Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech...
Foreseen Biotechnology
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...